• br Author contributions br Funding This work was supported b

  2023-03-08

  

  Author contributions Funding This work was supported by the Czech Science Foundation, project no. 14-16220S. Additional support was provided by NIH R01CA117907 grant awarded to J.M.E. Conflict of interest Introduction The dioxin-like family includes polyhalogenated aromatic hydrocarbons

• Adiponectin also works on AdipoR inducing extracellular Ca i

  2023-03-08

  

  Adiponectin also works on AdipoR1, inducing extracellular Ca2+ influx necessary for activation of Ca2+/calmodulin-dependent protein kinase kinase (CaMKK)β, AMPK (Fig. 1). This step is then followed by activation of SirT1 and increased expression and decreased acetylation of PPARγ coactivator (PGC)-1

• br Expression of ADK in

  2023-03-08

  

  Expression of ADK in the normal brain In adult brain, ADK is primarily expressed in astrocytes. Immunocytochemical analysis of adult rat and mouse PAC-1 revealed predominant astrocytic expression throughout the hippocampus and cortex. Two isoforms of ADK have been identified in mammals, a long n

• br Actin at presynapses br Conclusion

  2023-03-08

  

  Actin at presynapses Conclusion Thanks to the recent discovery of rings, hotspots and trails, axonal 11021 is back in the spotlight. These are exiting times for neuronal cell biologists armed with constantly improving labeling and imaging techniques to observe, quantify and perturb these stru

• br Conflict of interest statement br

  2023-03-07

  

  Conflict of interest statement Benign prostatic hyperplasia (BPH) is a highly complex process characterized by an increased number of epithelial and stromal γ-Secretase inhibitor IX in the transition zone. , , Autopsy studies by McNeal detail the evolution of histological changes within these

• For the NSCLC patients with EGFR activating mutations EGFR T

  2023-03-07

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• For the NSCLC patients with EGFR activating mutations EGFR T

  2023-03-07

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• For the NSCLC patients with EGFR activating mutations EGFR T

  2023-03-07

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• For the NSCLC patients with EGFR activating mutations EGFR T

  2023-03-07

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• Our data indicate that the D domain

  2023-03-07

  

  Our data indicate that the D1 domain only needs to hydrolyze ATP a few times, or perhaps even just once, during the processing of a given substrate molecule, whereas the D2 domain hydrolyzes ATP many times. Consistent with this model, only D2 contains the canonical aromatic pore loop residues implic

• In HepG cells compound showed inhibition

  2023-03-06

  

  In HepG2 cells, (R)-baclofen receptor showed inhibition of total lipid syntheses with an IC of 8μM. A cell based Alamar Blue cytotoxicity assay was used in parallel to differentiate the effect on the inhibition of lipid synthesis versus potential cytotoxicity. Under identical incubation conditions,

• In the case of DIA

  2023-03-06

  

  In the case of DIA-4CN the docking results do not show any interaction between the iron atom and the inhibitor, presumably due to the reduced ability to form a complex involving the -CONN- moiety versus the bidentate -CONHNH- central group of HYD-4Me. This results in a considerable gap between the i

• Two parallel branches of the

  2023-03-06

  

  Two parallel branches of the DNA damage-dependent S-phase checkpoint are thought to co-operate by inhibiting distinct steps of DNA replication. One branch includes the phosphorylation of structural maintenance of chromosomes 1 (SMC1), a cohesin that is activated by ATM or ATR after IR treatment or r

• The objectives of this study were to investigate the

  2023-03-06

  

  The objectives of this study were to investigate 1) the mRNA and protein expression of apelin and APJ in porcine ovarian follicles of different sizes, and their immunolocalization and concentrations in follicular fluid and ovarian follicle, and 2) the direct effect of recombinant human apelin-13 on

• Interestingly we found that co treatment with losartan

  2023-03-06

  

  Interestingly, we found that co-treatment with losartan prevented the increased participation of ROS from NADPH oxidase on the contractile response to Phe observed in Hg-treated rats. Moreover, losartan also prevented the reduction in the endothelial NO modulation of this response found in treated a

14897 records 265/994 page Previous Next First page 上5页 261262263264265 下5页 Last page